Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan

Abstract

Aims:

To evaluate treatment satisfaction before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy in patients with type 2 diabetes mellitus (T2D) in the IMPROVE study Japan using the Diabetes Medication Satisfaction (DiabMedSat) questionnaire.

Methods:

The DiabMedSat questionnaire assesses overall satisfaction with drug therapy for diabetes treatment in three domains: burden, efficacy and symptoms. Patients previously treated by oral anti-diabetic drugs in the IMPROVE study Japan answered the DiabMedSat questionnaires at baseline (week 0) and week 26 after starting BIAsp 30 treatment.

Results:

The mean scores for each domain at weeks 0 and 26, respectively, were: burden, 64.5 and 67.5 (p = 0.041); efficacy, 55.0 and 61.5 (p < 0.001); and symptoms, 70.9 and 68.1 (p = 0.049). The overall scores were 63.4 and 65.6, respectively (p = 0.079). With regard to burden, bothersome aspects were significantly improved with BIAsp 30 treatment at week 26, compared with treatment with oral anti-diabetic drugs at week 0. Major hypoglycemic episodes were very rare; most hypoglycemic events were minor and occurred during the daytime.

Conclusions:

The study results indicate that BIAsp 30 does not adversely affect QOL in Japanese patients at insulin initiation.

Key words::

• Biphasic insulin aspart 30
• DiabMedSat questionnaire
• Quality of life
• Treatment satisfaction
• Type 2 diabetes mellitus

Transparency

Declaration of funding

Novo Nordisk A/S provided the financial support for this study.

Declaration of financial/other relationships

Y.S. is employed by the Department of Safety Management, Novo Nordisk Pharma Ltd.

Acknowledgments

The authors wish to thank all patients and physicians at the 614 medical centers nationwide who participated in the IMPROVE study Japan.